Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial (vol 43, pg 465, 2024)

被引：0

|

作者：

Espay, A. J.

Stocchi, F.

Pahwa, R.

机构：

来源：

LANCET NEUROLOGY | 2024年 / 23卷 / 06期

关键词：

D O I：

10.1016/S1474-4422(24)00172-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：E10 / E10

页数：1

相关论文

共 50 条

[41] Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Moreira, Joana
Pereira, Ana
Rocha, Jose-Francisco
Soares-da-Silva, Patricio
NEUROLOGY AND THERAPY, 2022, 11 (03) : 1409 - 1425
[42] Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
Joaquim J. Ferreira
Werner Poewe
Olivier Rascol
Fabrizio Stocchi
Angelo Antonini
Joana Moreira
Ana Pereira
José-Francisco Rocha
Patrício Soares-da-Silva
Neurology and Therapy, 2022, 11 : 1409 - 1425
[43] Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial (vol 401, pg 1518, 2023)
McInnes, Iain B.
Merola, Joseph F.
LANCET, 2023, 401 (10392): : 1928 - 1928
[44] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)
Gordon, K. B.
Foley, P.
Krueger, J. G.
LANCET, 2021, 397 (10280): : 1182 - 1182
[45] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (vol 397, pg 2070, 2021)
Rovin, B. H.
Teng, Y. K. O.
Ginzler, E. M.
LANCET, 2021, 397 (10289): : 2048 - 2048
[46] Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial
Hanauer, Stephen
Liedert, Bernd
Balser, Sigrid
Brockstedt, Ekkehard
Moschetti, Viktoria
Schreiber, Stefan
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 816 - 825
[47] Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial (vol 22, pg 494, 2023)
Granit, V
Benatar, M.
Kurtoglu, M.
LANCET NEUROLOGY, 2023, 22 (09): : E10 - E10
[48] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 401, pg 1079, 2023)
Craig, T. J.
Reshef, A.
Li, H. H.
LANCET, 2023, 401 (10384): : 1266 - 1266
[49] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial (vol 22, pg 209, 2023)
Lipton, R. B.
Croop, R.
Stock, D. A.
LANCET NEUROLOGY, 2023, 22 (05): : e7 - e7
[50] NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Christine, Chadwick W.
LANCET NEUROLOGY, 2015, 14 (10): : 979 - 979

← 1 2 3 4 5 →